Ongoing phase II clinical trials MDX-1100-anti-CXCL10, indicated here by PPI analysis in closed pyometra, have been conducted in inflammatory bowel disease and rheumatoid arthritis [23]. This evidence concerns the gene CXCL10 and inflammatory bowel disease.